ABSTRACT

Background. DOG1 (ANO1; TMEM16A) is a voltage-gated calcium-activated chloride and bicarbonate channel. DOG1 is physiologically expressed in Cajal cells, where it plays an important role in regulating intestinal motility and its expression is a diagnostic hallmark of gastrointestinal stromal tumors (GIST). Data on a possible role of DOG1 in pancreatic cancer are rare and controversial. The aim of our study was to clarify the prevalence of DOG1 expression in pancreatic cancer and to study its association with parameters of cancer aggressiveness.

Methods. DOG1 expression was analyzed by immunohistochemistry in 599 pancreatic cancers in a tissue microarray format and in 12 cases of pancreatitis on large tissue sections.

Results. DOG1 expression was always absent in normal pancreas but a focal weak expression was seen in four of 12 cases of pancreatitis. DOG1 expression was, however, common in pancreatic cancer. Membranous and cytoplasmic DOG1 expression in tumor cells was highest in pancreatic ductal adenocarcinomas (61% of 444 interpretable cases), followed by cancers of the ampulla Vateri (43% of 51 interpretable cases), and absent in 6 acinus cell carcinomas. DOG1 expression in tumor associated stroma cells was seen in 76 of 444 (17%) pancreatic ductal adenocarcinomas and in seven of 51 (14%) cancers of the ampulla Vateri. Both tumoral and stromal DOG1 expression were unrelated to tumor stage, grade, lymph node and distant metastasis, mismatch repair protein deficiency and the density of CD8 positive cytotoxic T-lymphocytes in the subgroups of ductal adenocarcinomas and cancers of ampulla Vateri. Overall, the results of our study indicate that DOG1 may represent a potential biomarker for pancreatic cancer diagnosis and a putative therapeutic target in pancreatic cancer. However, DOG1 expression is unrelated to pancreatic cancer aggressiveness.
Subjects  Biochemistry, Molecular Biology, Gastroenterology and Hepatology, Oncology, Pathology
Keywords  DOG1, Immunohistochemistry, Pancreatic adenocarcinoma, Tissue micro array

INTRODUCTION

Pancreatic cancer is the 11th most frequent cancer, but the 2nd leading cause of cancer-related mortality in the United States of America (Global Cancer Observatory, 2020). Both the incidence and mortality are continuously rising (Rahib et al., 2014). The poor prognosis of pancreatic cancer results from the scarcity of early symptoms and consecutively a late diagnosis of locally advanced or metastatic cancers in most patients. The 5-year survival independent of the tumor stage remains at 8% (Siegel, Miller & Jemal, 2017). The histopathological diagnosis of pancreatic cancer can be challenging due to the often limited quantity of cells or tissue obtainable by fine needle aspiration/biopsy and considerable inflammation in the surroundings of these cancers (Mangiavillano et al., 2020).

DOG1 (Discovered On Gastrointestinal Stromal Tumors Protein 1), also known as Transmembrane Protein 16A (TMEM16A) or Anoctamin-1 (ANO1) is a voltage-gated calcium-activated chloride and bicarbonate channel (Caputo et al., 2008; Yang et al., 2008). DOG1 is highly expressed in the gastrointestinal interstitial cells of Cajal, where it plays an important role in epithelial chloride secretion mediating intestinal motility (Miettinen, Wang & Lasota, 2009; Chevalier et al., 2020). Calcium-activated chloride channel blocking drugs like niflumic acid have been shown to block slow waves (pacemaker activity)—which produce motility—in the human small intestine and stomach (Hwang et al., 2009).

High levels of DOG1 expression are a diagnostic hallmark of gastrointestinal stromal tumor (GIST), a tumor derived from these cells (Miettinen, Wang & Lasota, 2009; West et al., 2004; Kindblom et al., 1998; Sircar et al., 1999). However, DOG1 expression was also reported to occur in squamous cell carcinomas of the esophagus and head and neck, thyroid carcinomas, and adenocarcinomas of endometrium, stomach and colon (Miettinen, Wang & Lasota, 2009; Friedrich et al., 2016; Chenever et al., 2012; Hemminger & Iwenofu, 2012; Yu et al., 2019). Data on the prevalence and significance of DOG1 expression in pancreatic cancer are limited and partly controversial. In a study employing immunohistochemistry (IHC) on a tissue microarray (TMA), Hemminger et al. (2012) identified patchy low to moderate intensity DOG1 immunostaining in 8 (7%) of 112 pancreatic adenocarcinomas. In contrast, Crottes et al. (2019) scrutinized available databases for signs of up-regulation of DOG1 protein and mRNA in pancreatic adenocarcinoma and determined that DOG1 is up-regulated in 75% of pancreatic carcinomas. From data derived from the TCGA database, these authors further concluded that high levels of DOG1 were correlated with low patient survival probability. Evidence for a functionally active role of DOG1 in pancreatic cancer cells come from four previous studies showing elevated DOG1 expression in pancreatic cancer cell lines and demonstrating that inhibition, knockdown or knockout of DOG1 attenuates cell motility, migration, and proliferation and promotes cell cycle arrest in G0/G1 phase in vitro and in vivo (Crottes et al., 2019; Sauter et al., 2015; Stanich et al., 2011; Mazzone et al., 2012). Nielsen, Mortensen & Detlefsen (2018) described DOG1 expression to
also occur in pancreatic cancer associated fibroblasts. In a thorough study analyzing DOG1 expression in well-defined stroma compartments of eight pancreatic adenocarcinomas they found a higher rate of DOG1 expression in cancer-associated fibroblasts (CAFs) that were located in the immediate neighborhood of cancer cells (juxtatumoral stroma) than in the cancer periphery (peritumoral stroma).

The aims of this study were to clarify the prevalence of DOG1 expression in epithelial and stromal cells of pancreatic carcinomas and to identify potential associations with parameters of cancer aggressiveness. For this purpose, a cohort of 599 pancreatic carcinomas was analyzed for DOG1 expression by IHC in a TMA format.

**MATERIALS & METHODS**

**Tissue microarray**

The 599 samples were diagnosed at the Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany: 532 ductal adenocarcinomas, 61 adenocarcinomas of the ampulla Vateri, and 6 acinar cell carcinomas. The TMA was made as described in Kononen et al. (1998). Clinico-pathological parameters were obtained from the pathology reports (Table 1). The molecular database attached to the TMA contained results on mismatch repair deficiency (dMMR, surrogate for microsatellite instability, MSI) measured by MLH1, MSH2, PMS2, and MSH6 immunohistochemistry in 519 cases from a previous study (Fraune et al., 2020) and the density of CD8 positive cytotoxic T-lymphocytes in 599 cases (Blessin et al., 2020). Large sections from 12 pancreatectomy specimens from patients with pancreatitis not suffering from carcinoma were also analyzed.

The use of archived material for research purpose as well as patient data analysis has been approved by local laws (HmbKHG, §12) and by the ethics committee of Hamburg (WF-049/09). The work was done in compliance with the Helsinki Declaration.

**Immunohistochemistry**

TMA sections were freshly cut, processed and stained the same day. Slides were deparaffinized with xylol, rehydrated and exposed to heat-induced antigen retrieval. Endogenous peroxidase activity was blocked with Dako Peroxidase Blocking Solution (#52023; Agilent, Santa Clara, CA, USA) for 10 min. Anti-DOG1 mouse monoclonal antibody MSVA-201M (MS Validated Antibodies, Hamburg, Germany) was applied at 37 °C, 60 min, at 1:150. Staining was visualized with the EnVision Kit (#K5007; Agilent, Santa Clara, CA, USA) and counterstained with Haemalaun. DOG1 staining was predominantly membranous in pancreatic cancer cells. Scoring of the staining intensity was semi-quantitatively assessed as previously described in Juhnke et al. (2017). Specifically, four grades were defined: Negative (no staining at all), weak (staining intensity of 1+ in ≤70% of the tumor cells or staining intensity of 2+ in ≤30% of the tumor cells), moderate (staining intensity of 1+ in >70% of the tumor cells, staining intensity of 2+ in >30% but in ≤70% of the tumor cells or staining intensity of 3+ in ≤30% of the tumor cells), strong (staining intensity of 2+ in >70% of the tumor cells or staining intensity of 3+ in >30% of the tumor cells).
Table 1  Patient cohort.

|                      | all tumors (n = 599) |
|----------------------|----------------------|
| **Tumor type**       |                      |
| ductal adenocarcinoma| 532 (89%)            |
| acinar cell carcinoma| 6 (1%)               |
| adenocarcinoma of the ampulla Vaterii | 61 (10%) |
| **Tumor stage**      |                      |
| pT1                  | 20 (3%)              |
| pT2                  | 93 (16%)             |
| pT3                  | 435 (73%)            |
| pT4                  | 49 (8%)              |
| **Grade**            |                      |
| 1                    | 19 (3%)              |
| 2                    | 420 (74%)            |
| 3                    | 130 (23%)            |
| **Lymph node status**|                      |
| pN0                  | 135 (23%)            |
| pN+                  | 461 (77%)            |
| **Distant metastasis**|                     |
| pM0                  | 474 (79%)            |
| pM1                  | 123 (21%)            |
| **Surgical margin status**|                  |
| R0                   | 324 (58%)            |
| R1                   | 231 (42%)            |

**Statistics**

JMP® software (SAS Institute Inc., Cary, NC, USA) was used for contingency tables and chi²-tests to search for associations between DOG1 expression and histological subtypes, clinico-pathological parameters and dMMR. A p-value ≤ 0.05 was considered as statistically significant.

**RESULTS**

**Technical issues**

On our TMA, 501 of 599 (83.6%) pancreatic cancers were analyzable in the DOG1 IHC analysis. Reasons for non-informative cases (n = 98, 16.4%) included lack of tissue samples or absence of unequivocal cancer tissue in the TMA spot.

**DOG1 expression in pancreatic cancers**

DOG1 immunostaining could be observed in both cancer cells and in tumor associated stromal cells. A predominantly membranous cancer cell staining was seen in 294 (58.7%) of the 501 interpretable cancers. The observed staining pattern were variable and ranged from focal staining of various intensity to intense diffuse positivity. Stroma cell staining was often periglandular or “juxtatumoral” but did also involve cells that were more remote from
cancer cells. Representative images are shown in Fig. 1. The frequency of DOG1 positive cancer cell staining was highest in ductal adenocarcinomas (61.3%; \(n = 444\)), followed by adenocarcinomas of the ampulla of Vateri (43.1%; \(n = 51\)). DOG1 positive stromal cells were found in 76 of 444 (17.1%) ductal adenocarcinomas, and 7 of 51 (13.7%) adenocarcinomas of the ampulla of Vateri. DOG1 immunostaining both tumoral and stromal was absent in acinar cell carcinoma \((n = 6)\). DOG1 staining was also completely absent in normal pancreatic cells. A weak to moderate focal DOG1 staining was seen, however, in 4 of 12 large sections of pancreatitis cases. Statistical associations were not observed between both stromal and tumor cell DOG1 staining and clinico-pathological parameters in the analysis of ductal adenocarcinomas of the pancreas \((p > 0.1\) each; Tables 2 and 3) and of cancers of the ampulla Vateri \((p > 0.5\) each except of pT with \(p = 0.0104\); Tables 2 and 3). DOG1 staining was also unrelated to dMMR and the density of CD8 positive lymphocytes in ductal adenocarcinomas and adenocarcinomas of the ampulla of Vateri \((p ≥ 0.1; \text{Tables 2–4})\).

**DISCUSSION**

The results of our study demonstrate that tumoral DOG1 expression is frequent in both ductal adenocarcinoma of the pancreas (61.3% of 444 cancers) and adenocarcinomas of the ampulla Vateri (43.1% of 51 cancers). This observation is consistent with data derived from large databases on RNA and protein expression in cancers. Crottes et al. (2019) had scrutinized available databases for signs of up-regulation of DOG1 mRNA and protein expression in pancreatic adenocarcinoma and determined that DOG1 was up-regulated in 75% of pancreatic cancers. Our frequency of tumoral DOG1 immunostaining in pancreatic cancer is markedly higher than in the only previous study investigating DOG1 expression by IHC. In a study analyzing 112 pancreatic adenocarcinomas in a TMA format, Hemminger et al. (2012) found a weak to moderate DOG1 positivity in 8 (7%) of all carcinomas. The use of different antibodies, staining protocols, and criteria for defining positivity are the most common causes for different outcomes of studies employing IHC (Janardhan et al., 2018). In addition, in case of TMA studies, the time span between the cutting of the TMA section and its immunohistochemical staining has a marked impact on the staining intensity of many antibodies. Even a slide age of two weeks can lead to a marked reduction of staining (Mirlacher et al., 2004).

Beside the expression of DOG1 in tumor cells, Nielsen et al. (2020) have recently shown that DOG1 can also be expressed in CAFs. In their study, Nielsen et al. focused on the analysis of the tumor microenvironment—especially the juxtatumoral, peripheral, lobular, septal, peripancreatic, and regressive stroma compartments—of chemotherapy-naïve (CTN-PC; \(n = 10\)) and neoadjuvant treated (NAT-PC; \(n = 10\)) pancreatic adenocarcinomas and found that DOG1 was particularly overexpressed in CAFs that were located in close contact to cancer cells (juxtatumoral CAFs). The authors concluded from their data that juxtatumoral CAFs characterized by strong DOG1 expression and several other markers might promote the proliferation and invasion of cancer cells. A pathogenetic role of DOG1 expression in CAFs is potentially also supported by our data, as DOG1 expressing fibroblasts...
**Figure 1** DOG1 immunostaining. (A–D) DOG1 positive ductal adenocarcinomas with strong (A), moderate (B), focal moderate (C), and weak immunostaining of tumor cells (D). (A) and (C) also contain DOG1 negative normal ducts (arrow). (E & F) DOG1 negative cancers with diffuse (E) and periductal DOG1 (F) staining of stromal cells (F).
Table 2  DOG1 immunostaining in cancer cells and cancer phenotype.

|                          | n evaluable | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | p value |
|--------------------------|-------------|--------------|----------|--------------|------------|---------|
| Ductal adenocarcinomas   |             |              |          |              |            |         |
| Tumor stage              |             |              |          |              |            |         |
| pT1                      | 12          | 16.7         | 25       | 25           | 33.3       | 0.5262  |
| pT2                      | 62          | 35.5         | 27.4     | 22.6         | 14.5       |         |
| pT3-4                    | 368         | 39.7         | 26.1     | 16.8         | 17.4       |         |
| Grade                    |             |              |          |              |            |         |
| 1                        | 11          | 36.4         | 18.2     | 18.2         | 27.3       |         |
| 2                        | 317         | 40.1         | 25.2     | 18           | 16.7       | 0.4193  |
| 3                        | 94          | 27.7         | 31.9     | 19.1         | 21.3       |         |
| Lymph node status        |             |              |          |              |            |         |
| pN0                      | 89          | 44.9         | 23.6     | 15.7         | 15.7       | 0.5912  |
| pN+                      | 352         | 36.9         | 26.7     | 18.5         | 17.9       |         |
| Surgical margin status   |             |              |          |              |            |         |
| R0                       | 219         | 37.4         | 23.3     | 19.2         | 20.1       |         |
| Mismatch repair          |             |              |          |              |            |         |
| intact                   | 400         | 39.3         | 26       | 17           | 17.8       | 0.5187  |
| deficent                 | 3           | 33.3         | 0        | 33.3         | 33.3       |         |
| Adenocarcinoma of the ampulla Vaterii |             |              |          |              |            |         |
| Tumor stage              |             |              |          |              |            |         |
| pT1                      | 3           | 0            | 66.7     | 0            | 33.3       |         |
| pT2                      | 9           | 22.2         | 22.2     | 44.4         | 11.1       | 0.0104  |
| pT3-4                    | 39          | 69.2         | 12.8     | 7.7          | 10.3       |         |
| Grade                    |             |              |          |              |            |         |
| 1                        | 0           | –            | –        | –            | –          |         |
| 2                        | 33          | 54.5         | 18.2     | 18.2         | 9.1        | 0.5299  |
| 3                        | 18          | 61.1         | 16.7     | 5.6          | 16.7       |         |
| Lymph node status        |             |              |          |              |            |         |
| pN0                      | 11          | 45.5         | 18.2     | 36.4         | 0          | 0.0595  |
| pN+                      | 40          | 60           | 17.5     | 7.5          | 15         |         |
| Surgical margin status   |             |              |          |              |            |         |
| R0                       | 43          | 55.8         | 14       | 16.3         | 14         | 0.1841  |
| Mismatch repair          |             |              |          |              |            |         |
| intact                   | 48          | 56.3         | 18.8     | 12.5         | 12.5       | –        |
| deficent                 | 0           | –            | –        | –            | –          | –        |

were seen in 17% of pancreatic adenocarcinomas but neither in normal pancreas nor in chronic pancreatitis.

That DOG1 expression in tumor or stromal cells did not show any associations with tumor stage, grade, or nodal and distant metastasis in our study argues against a clinically significant impact of DOG1 expression on pancreatic cancer aggressiveness. This is in contrast with data derived from Crottès et al. from the TCGA database, where high levels of TMEM16A were linked to a low patient survival probability in a cohort of 146 patients (Crottes et al., 2019). Comparing protein expression measured by IHC and RNA expression data is particularly challenging in pancreatic cancer because of the high average stroma content of this tumor (Feig et al., 2012). RNA data may therefore be highly diluted in
Table 3  DOG1 immunostaining in stroma cells and cancer phenotype.

|                          | n evaluable | Negative (%) | Positive (%) | p value |
|--------------------------|-------------|--------------|--------------|---------|
| **DOG1 immunostaining in stroma cells** |             |              |              |         |
| **Ductal adenocarcinomas** |             |              |              |         |
| Tumor stage              |             |              |              |         |
| pT1                      | 12          | 91.7         | 8.3          | 0.4117  |
| pT2                      | 62          | 87.1         | 12.9         |         |
| pT3-4                    | 368         | 82.1         | 17.9         |         |
| Grade                    |             |              |              |         |
| 1                        | 11          | 81.8         | 18.2         | 0.8236  |
| 2                        | 317         | 83.6         | 16.4         |         |
| 3                        | 94          | 80.9         | 19.2         |         |
| Lymph node status        |             |              |              |         |
| pN0                      | 89          | 82.0         | 18.0         | 0.8359  |
| pN+                      | 352         | 83.0         | 17.1         |         |
| Surgical margin status   |             |              |              |         |
| R0                       | 219         | 81.3         | 18.7         | 0.4064  |
| R1                       | 192         | 84.4         | 15.6         |         |
| Mismatch repair          |             |              |              |         |
| intact                   | 400         | 83.2         | 16.8         | 0.4885  |
| deficent                 | 3           | 66.7         | 33.3         |         |
| **Adenocarcinoma of the ampulla Vaterii** |             |              |              |         |
| Tumor stage              |             |              |              |         |
| pT1                      | 3           | 66.7         | 33.3         | 0.1748  |
| pT2                      | 9           | 100.0        | 0.0          |         |
| pT3-4                    | 39          | 84.6         | 15.4         |         |
| Grade                    |             |              |              |         |
| 1                        | 0           | –            | –            | 0.1825  |
| 2                        | 33          | 81.8         | 18.2         |         |
| 3                        | 18          | 94.4         | 5.6          |         |
| Lymph node status        |             |              |              |         |
| pN0                      | 11          | 81.8         | 18.2         | 0.6374  |
| pN+                      | 40          | 87.5         | 12.5         |         |
| Surgical margin status   |             |              |              |         |
| R0                       | 43          | 86.1         | 14.0         | 0.9813  |
| R1                       | 7           | 85.7         | 14.3         |         |
| Mismatch repair          |             |              |              |         |
| intact                   | 48          | 84.8         | 15.2         | –       |
| deficent                 | 0           | –            | –            | –       |

many of pancreatic cancers and partly reflect tumor cell density. Moreover, if cancers are preselected for high tumor cell content, a selection bias may apply. It may well be that associations between molecular drivers of cancer aggressiveness and unfavorable tumor features are—due to their overall very poor prognosis—particularly difficult to identify in pancreatic cancer. That the density of CD8 positive cytotoxic T-lymphocytes did not vary between tumors expressing different levels of DOG1 argues against a particular role

Jansen et al. (2021), *PeerJ*, DOI 10.7717/peerj.11905
| DOG1 in cancer cells | n evaluable | CD8 density (cells/mm²) | p value |
|----------------------|-------------|-------------------------|---------|
| Ductal adenocarcinomas | negative 172 | 239.6 ± 21.9 | |
|                      | weak 116    | 226.0 ± 26.7 | 0.7658 |
|                      | moderate 79 | 197.8 ± 32.4 | |
|                      | strong 77   | 226.8 ± 32.8 | |
| Adenocarcinoma of the ampulla Vaterii | negative 29 | 291.1 ± 78.8 | |
|                      | weak 9      | 121.7 ± 141.5 | 0.1048 |
|                      | moderate 7  | 637.1 ± 160.5 | |
|                      | strong 6    | 179.6 ± 173.3 | |

| DOG1 in stroma cells | n evaluable | CD8 density (cells/mm²) | p value |
|----------------------|-------------|-------------------------|---------|
| Ductal adenocarcinomas | negative 368 | 227.7 ± 15.0 | |
|                      | positive 76  | 220.1 ± 33.0 | 0.8326 |
| Adenocarcinoma of the ampulla Vaterii | negative 44 | 318.4 ± 66.3 | |
|                      | positive 7   | 152.3 ± 166.2 | 0.3577 |

The data from this study also suggest a potential diagnostic utility of DOG1 IHC in pancreatic cancer. Since DOG1 expression was detectable in more than 60% of pancreatic adenocarcinomas and >40% of adenocarcinomas of the ampulla Vateri, but completely absent in normal pancreatic tissues, a positive DOG1 immunostaining in a pancreatic biopsy may serve as an argument for malignancy. It is of note, however, that DOG1 expression alone cannot secure a diagnosis of pancreatic cancer as weak to moderate focal DOG1 immunostaining was also observed in four of 12 pancreatitis specimens in our study. Current panels that are used to support the diagnosis of malignancy in pancreatic cancer likely need to be expanded to include DOG1.
biopsies typically include CA19-9, CK7, CK19, MUC1, and CEA, (Wong & Chu, 2012) and could be complemented by DOG1.

CONCLUSIONS

In summary, the results of this study show that DOG1 is frequently expressed in pancreatic adenocarcinoma. Although DOG1 expression is unrelated to parameters of cancer aggressiveness, it may be a suitable diagnostic marker and an excellent therapeutic target in pancreatic cancer.

ACKNOWLEDGEMENTS

We are grateful to Melanie Witt, Inge Brandt, Maren Eisenberg, and Sünje Seekamp for excellent technical assistance.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

The DOG1 antibody clone MSVA-201M was received from MS Validated Antibodies GmbH (owned by a family member of Guido Sauter).

Author Contributions

• Kristina Jansen, Ronald Simon and Till Clauditz conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Franziska Büscheck, Katharina Moeller, Martina Kluth, Claudia Hube-Magg, Niclas Christian Blessin, Christoph Fraune, Frank Jacobsen, Christian Bernreuther and Patrick Lebok conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Daniel Perez, Jakob Izbicki, Michael Neipp, Hamid Mofid, Thies Daniels and Ulf Nahrstedt conceived and designed the experiments, performed the experiments, prepared figures and/or tables, collection of samples, and approved the final draft.
• Guido Sauter and Waldemar Wilczak conceived and designed the experiments, performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Ria Uhlig performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Stefan Steurer and Eike Burandt conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Andreas Marx and Till Krech conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, collection of samples, and approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The use of archived remnants of diagnostic tissues for manufacturing of tissue microarrays and their analysis for research purpose as well as patient data analysis has been approved by local laws (HmbKHG, §12) and by the local ethics committee (Ethics Commission Hamburg, WF-049/09). All work has been carried out in compliance with the Helsinki Declaration.

Data Availability
The following information was supplied regarding data availability:

The raw data of DOG1 immunostaining obtained from the pancreatic cancer tissue microarray are available in the Supplemental File.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.11905#supplemental-information.

REFERENCES

Berglund E, Akcakaya P, Berglund D, Karlsson F, Vukojevic V, Lee L, Bogdanovic D, Lui WO, Larsson C, Zedenius J, Frobom R, Branstrom R. 2014. Functional role of the Ca(2)(+)–activated Cl(-) channel DOG1/TMEM16A in gastrointestinal stromal tumor cells. *Experimental Cell Research* 326(2):315–325 DOI 10.1016/j.yexcr.2014.05.003.

Bill A, Gutierrez A, Kulkarni S, Kemp C, Bonenfant D, Voshol H, Duvvuri U, Gaither LA. 2015. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. *Oncotarget* 6(11):9173–9188 DOI 10.18632/oncotarget.3277.

Blessin NC, Li W, Mandelkow T, Jansen HL, Yang C, Raedler JB, Simon R, Büscheck F, Dum D, Luebke AM, Hinsch A, Möller K, Menz A, Bernreuther C, Lebok P, Clauditz T, Sauter G, Marx A, Uhlig R, Wilczak W, Minner S, Krech T, Fraune C, Höflmayer D, Burandt E, Steurer S. 2021. Prognostic role of proliferating CD8+ cytotoxic T-cells in human cancers. *Clinical & Translational Immunology* Epub ahead of print Apr 17 2021.

Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, Rebhan M, Raman P, Guy CT, Wetzel K, George E, Popa MO, Lilley S, Choudhury H, Gosling M, Wang L, Fitzgerald S, Borawski J, Baffoe J, Labow M, Gaither LA, Bentires-Alj M. 2013. Calcium-activated chloride channel ANO1 promotes breast cancer
progression by activating EGFR and CAMK signaling. *Proceedings of the National Academy of Sciences of the United States of America* **110**(11):E1026–34 DOI 10.1073/pnas.1217072110.

Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O, Galietta LJ. 2008. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. *Science* **322**(5901):590–594 DOI 10.1126/science.1163518.

Chenevert J, Duvvuri U, Chiosea S, Dacic S, Cieply K, Kim J, Shiwarski D, Seethala RR. 2012. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. *Modern Pathology* **25**(7):919–929 DOI 10.1038/modpathol.2012.57.

Chevalier NR, Ammouche Y, Gomis A, Teyssaire C, De Santa Barbara P, Faure S. 2020. Shifting into high gear: how interstitial cells of Cajal change the motility pattern of the developing intestine. *American Journal of Physiology. Gastrointestinal and Liver Physiology* **319**(4):G519–G28 DOI 10.1152/ajpgi.00112.2020.

Crottes D, Lin YT, Peters CJ, Gilchrist JM, Wiita AP, Jan YN, Jan LY. 2019. TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis. *Proceedings of the National Academy of Sciences of the United States of America* **116**(26):13026–13035 DOI 10.1073/pnas.1900703116.

Duvvuri U, Shiwarski DJ, Xiao D, Bertr C, Huang X, Edinger RS, Rock JR, Harfe BD, Henson BJ, Kunzelmann K, Schreiber R, Seethala RS, Egloff AM, Chen X, Lui VW, Grandis JR, Gollin SM. 2012. TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. *Cancer Research* **72**(13):3270–3281 DOI 10.1158/0008-5472.CAN-12-0475-T.

Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. 2012. The pancreas cancer microenvironment. *Clinical Cancer Research* **18**(16):4266–4276 DOI 10.1158/1078-0432.CCR-11-3114.

Fraune C, Burandt E, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Buscheck F, Hofmayer D, Blessin NC, Mandelkow T, Li W, Perez D, Izbicki JR, Wilczak W, Sauter G, Schrader J, Neipp M, Mofid H, Daniels T, Isbert C, Clauditz TS, Steurer S. 2020. MMR deficiency is homogeneous in pancreatic carcinoma and associated with high density of CD8-Positive Lymphocytes. *Annals of Surgical Oncology* **27**:3997–4006.

Friedrich RE, Wunder T, Schumacher U, Bartel-Friedrich S, Zustin J. 2016. Expression of DOG1 (Using SP31) in poorly differentiated carcinoma of the head and neck. *Anticancer Research* **36**(6):3117–3122.

Frobnom R, Sellberg F, Xu C, Zhao A, Larsson C, Lui WO, Nilsson IL, Berglund E, Branstrom R. 2019. Biochemical inhibition of DOG1/TMEM16A achieves anti-tumoral effects in human gastrointestinal stromal tumor cells in vitro. *Anticancer Research* **39**(7):3433–3442 DOI 10.21873/anticancer.13489.

Fujimoto M, Inoue T, Kito H, Niwa S, Suzuki T, Muraki K, Ohya S. 2017. Transcriptional repression of HER2 by ANO1 Cl– channel inhibition in human breast cancer cells with resistance to trastuzumab. *Biochemical and Biophysical Research Communications* **482**(1):188–194 DOI 10.1016/j.bbrc.2016.11.033.
Global Cancer Observatory. 2020. Cancer today. International Agency for Research on Cancer. Available at https://gco.iarc.fr/today (accessed on 28 October 2020).

Guan L, Song Y, Gao J, Gao J, Wang K. 2016. Inhibition of calcium-activated chloride channel ANO1 suppresses proliferation and induces apoptosis of epithelium originated cancer cells. Oncotarget 7(48):78619–78630 DOI 10.18632/oncotarget.12524.

Hemminger J, Iwenofu OH. 2012. Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms. Histopathology 61(2):170–177 DOI 10.1111/j.1365-2559.2011.04150.x.

Hemminger J, Marsh WL, Iwenofu OH, Frankel WL. 2012. DOG1 (clone K9) is seldom expressed and not useful in the evaluation of pancreatic neoplasms. Appl Immunohistochem Mol Morphol 20(4):397–401 DOI 10.1097/PAI.0b013e318246c345.

Hu C, Zhang R, Jiang D. 2019. TMEM16A as a potential biomarker in the diagnosis and prognosis of lung cancer. Archives of Iranian Medicine 22(1):32–38.

Hwang SJ, Blair PJ, Britton FC, O'Driscoll KE, Hennig G, Bayguinov YR, Rock JR, Harfe BD, Sanders KM, Ward SM. 2009. Expression of anoctamin 1/TMEM16A by interstitial cells of Cajal is fundamental for slow wave activity in gastrointestinal muscles. Journal de Physiologie 587(Pt 20):4887–4904 DOI 10.1113/jphysiol.2009.176198.

Janardhan KS, Jensen H, Clayton NP, Herbert RA. 2018. Immunohistochemistry in investigative and toxicologic pathology. Toxicologic Pathology 46(5):488–510 DOI 10.1177/0192623318776907.

Juhnke M, Heumann A, Chirico V, Höflmayer D, Menz A, Hinsch A, Hube-Magg C, Kluth M, Lang DS, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe R, Thederan I, Schlimm T, Luebke AM. 2017. Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion. Molecular Carcinogenesis 56(9):2135–2145 DOI 10.1002/mc.22670.

Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. 1998. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology 152(5):1259–1269.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. 1998. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine 4(7):844–847 DOI 10.1038/nm0798-844.

Kulkarni S, Bill A, Godse NR, Khan NI, Kass JI, Stehleler K, Kemp C, Davis K, Bertr CA, Vyas AR, Holt DE, Grandis JR, Gaither LA, Duvvuri U. 2017. TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2. Genes Chromosomes Cancer 56(6):460–471 DOI 10.1002/gcc.22450.

Mangiavillano B, Sosa-Valencia L, Deprez P, Eisendrath P, Robles-Medranda C, Eusebi LH, Di Leo M, Auricemma F, Bianchetti M, Anderloni A, Carrara S, Repici A. 2020. Tissue acquisition and pancreatic masses: which needle and which acquisition technique should be used? Endoscopy International Open 8(10):E1315–E20 DOI 10.1055/a-1221-4578.
Mazzone A, Eisenman ST, Strege PR, Yao Z, Ordog T, Gibbons SJ, Farrugia G. 2012. Inhibition of cell proliferation by a selective inhibitor of the Ca(2+)-activated Cl(-) channel, Ano1. Biochemical and Biophysical Research Communications 427(2):248–253 DOI 10.1016/j.bbrc.2012.09.022.

Miettinen M, Wang ZF, Lasota J. 2009. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. American Journal of Surgical Pathology 33(9):1401–1408 DOI 10.1097/PAS.0b013e3181a90c1a.

Mirlacher M, Kasper M, Storz M, Knecht Y, Durmuller U, Simon R, Mihatsch MJ, Sauter G. 2004. Influence of slide aging on results of translational research studies using immunohistochemistry. Modern Pathology 17(11):1414–1420 DOI 10.1038/modpathol.3800208.

Nielsen MFB, Mortensen MB, Detlefsen S. 2018. Typing of pancreatic cancer-associated fibroblasts identifies different subpopulations. World Journal of Gastroenterology 24(41):4663–4678 DOI 10.3748/wjg.v24.i41.4663.

Nielsen MFB, Mortensen MB, Sorensen MD, Wirenfeldt M, Kristensen BW, Schroder HD, Pfeiffer P, Detlefsen S. 2020. Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. Histology & Histopathology 35(8):811–825.

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Flesham JM, Matrisian LM. 2014. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research 74(11):2913–2921 DOI 10.1158/0008-5472.CAN-14-0155.

Sauter DRP, Novak I, Pedersen SF, Larsen EH, Hoffmann EK. 2015. ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC). Pflugers Archiv. European Journal of Physiology 467(7):1495–1508 DOI 10.1007/s00424-015-1598-8.

Siegel RL, Miller KD, Jemal A. 2017. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67(1):7–30.

Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. 1999. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. American Journal of Surgical Pathology 23(4):377–389 DOI 10.1097/00000478-199904000-00002.

Stanich JE, Gibbons SJ, Eisenman ST, Bardsley MR, Rock JR, Harfe BD, Ordog T, Farrugia G. 2011. Ano1 as a regulator of proliferation. American Journal of Physiology. Gastrointestinal and Liver Physiology 301(6):G1044–G1051 DOI 10.1152/ajpgi.00196.2011.

West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, Vande Rijn M. 2004. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. American Journal of Pathology 165(1):107–113 DOI 10.1016/S0002-9440(10)63279-8.

Wong HH, Chu P. 2012. Immunohistochemical features of the gastrointestinal tract tumors. Journal of Gastrointestinal Oncology 3(3):262–284.

Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee J, Lee B, Kim BM, Raouf R, Shin YK, Oh U. 2008. TMEM16A confers receptor-activated...
calcium-dependent chloride conductance. *Nature* **455**(7217):1210–1215 DOI 10.1038/nature07313.

Yu Y, Cao J, Wu W, Zhu Q, Tang Y, Zhu C, Dai J, Li Z, Wang J, Xue L, Zhen F, Liu J, Huang C, Zhao F, Zhou Y, Wen W, Pan X, Wei H, Zhu Y, He Y, Que J, Wang W, Luo J, Xu J, Chen L. 2019. Genome-wide copy number variation analysis identified ANO1 as a novel oncogene and prognostic biomarker in esophageal squamous cell cancer. *Carcinogenesis* **40**(10):1198–1208 DOI 10.1093/carcin/bgz077.